ACAAI 2024 ANNUAL SCIENTIFIC MEETING
Podium to Practice - Advancing Allergy / Immunology Discovery
October 24 - 28, 2024
Boston, MA
Submission Deadline: Monday, August 1, 2024 (5:00 pm CDT).
The College invites you to submit an abstract for the 2024 Annual Scientific Meeting, October 24 - 28, Boston, MA.
Medically Challenging Case Abstract Submission
All accepted Abstracts will be published online as they appear within the ACAAI System as of the deadline date. No changes can be made to the abstract after the close of the submission period.
Fellows-in-Training
Medically Challenging Case (MCC) Submissions
MCC Abstracts are an opportunity to present interesting and challenging cases you have management in your hospital or practice. Abstracts in the MCC category can describe the medical management in single or small series of patient cases that highlight:
A limit of 5 authors (total) per abstract may be included.
Authorship. The College follows the ICMJE quidelines. The ICMJE recommends that authorship be based on the following 4 criteria:
NOTE: All correspondence regarding the abstract submission will be sent to the abstract submitter at the email address provided at time of submission. It is the responsibility of the submitter to ensure that all information is correct and approved by the participating authors.
SUBMITTER INFORMATION
As the submitter, you will be the main contact person for the abstract, and as such, it will be your responsibility to make sure the other authors are informed of any communications from ACAAI regarding the abstract (including requests from the Abstract Review Subcommittee for additional information, disposition and placement decision, missing disclosures, etc.). If you are unwilling or unable to function in this capacity, please designate someone else as the contact person.Commercial Bias. All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection.
Abstract Withdrawal. If the Submitter wishes to withdraw his/her abstract from the Annual Meeting program, a written request must be submitted to education@acaai.org by August 1, 2024.
Employees of pharmaceutical or medical device companies or other ACCME-defined *ineligible company(ies) are prohibited from participating as an author or presenter of an oral abstract chosen for presentation during a CME Session; however, they may participate as an author or presenter for an electronic poster session, or an abstract chosen for oral presentation during a non-CME Oral Abstracts session.
*ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies
CME Financial Disclosure
In accordance with the ACCME Standards for Commercial Support the American College of Allergy, Asthma & Immunology (ACAAI), as an accredited provider, must ensure all CME Planners, Speakers, Presenters, Authors involved in the development of CME content and/or presentation of content, disclose to the accredited provider ALL*financial relationship(s) with any ACCME-defined **ineligible company(ies) [see definition of ineligible company below].
**ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies
All authors must complete the online Disclosure of Financial Relationships by August 1, 2024 or their names will be pulled as an abstract author.
Disclosure of relevant financial relationships includes the name of the ineligible company and the relationship.
REQUIRED INFORMATION FOR EACH AUTHOR:
ORGANIZATION OF ABSTRACT BODY
Title
There is a limit of 15 words for the abstract title. Use only standard alpha/numeric characters in your title. Do not use symbols. Capitalize the first letter of each word of the title. Do not use formatting tags in the title. The title will be formatted automatically by the system at the time of online production. Abbreviations must not be used in the title. The system does not monitor for Title character count. Check to ensure that you have not exceeded the word count limit.
Abstract Length
There is a limit of 250 words for the body of your abstract submission.
Abstract Body
Format the abstract body to include: "Introduction", "Case Description" and "Discussion". Do Not include company names or brand names within the abstract.
The abstract must contain the words "Introduction", "Case Description" and "Discussion" in the body of your abstract to indicate the start of each new section. The abstract title and author information must not be included in the body of the abstract. Do not include references within the body of your abstract.
Best Results. Best results are achieved by typing directly into the "body" area of the submission form. If you are entering the copy directly onto the Abstract Form, you must use the “Symbols” icon to ensure your results are displayed accurately. Always verify that your information is correct prior to submitting by selecting "Print Preview."
Editorial Policies for Authors (ICMJE Guidance)
Reproduced Materials - When previously published figures or tables are used, the author must obtain written permission from the copyright holder (usually the publisher) to reproduce the material. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be cited in the reference list. Letters of permission must accompany the manuscript at the time of submission.
Use of Figures. You may add one figure to your abstract, however, it is recommended that results be shown in narrative form, since figure formats may be compromised in publication. The figure must be submitted as a jpg file and cannot exceed 500kb.
Medically Challenging Case Abstract Acceptance.
To increase your opportunity of MCC abstract acceptance, submitters are encouraged to include their Program Director as an abstract reviewer in advance of final submission.
If the abstract is accepted for presentation at the ACAAI 2024 Annual Meeting, the submitter will be notified via email in late August/early September. Only the submitter will be notified of abstract presentation programming. Please ensure that all contact information is accurate. The notification will include the scheduled date, time and location of the presentation.
For your convenience, all abstract accepted for poster presentation for the ACAAI 2024 Annual Meeting will be displayed electronically. Complete details regarding the electronic posters will be sent to the submitter of accepted abstracts in late August/early September.
Abstracts accepted for presentation will be grouped by topic, numbered and listed in the program and published in the online October issue of the Annals of Allergy, Asthma and Immunology abstract supplement. The decision of the ACAAI Abstract Review Subcommittee regarding acceptance and presentation of abstracts is final.
Meeting Registration. All Presenting Authors must register for, and attend the ACAAI 2024 Meeting in Boston and pay any applicable registration fees. The meeting registration site will open in late July/early August.